abuse-deterrent opioid

From Aaushi
Jump to navigation Jump to search

Notes

More general terms

References

  1. 1.0 1.1 Orciari Herman A, Sadoughi S, Sofair A Safety of Abuse-Deterrent Painkillers Overestimated Physician's First Watch, June 8, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
  2. FDA News Release, March 24, 2016 FDA takes important step to increase the development of, and access to, abuse-deterrent opioids. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm492237.htm
    U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2016 General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products. Guidance for Industry. DRAFT GUIDANCE http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM492172.pdf
  3. FDA Statement. June 13, 2017 Statement from FDA Commissioner Scott Gottlieb, M.D. - FDA is taking new steps to help assess opioid drugs with abuse-deterrent properties. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562961.htm
  4. 4.0 4.1 NEJM Knowledge+ Pain Management and Opioids: Recharge
    Litman RS, Pagan OH, Cicero TJ. Abuse-deterrent Opioid Formulations. Anesthesiology. 2018 May;128(5):1015-1026. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29252508 Free article. Review.
    Coplan PM, Chilcoat HD, Butler SF et al The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse- related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016 Sep;100(3):275-86. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27170195 PMCID: PMC5102571 Free PMC article.